Heart Failure, Kidney Disease, Chronic
Conditions
Keywords
FGF23, klotho, Mineral Bone Disorder
Brief summary
the objective of this study is to : -Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.
Detailed description
The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality. Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho. The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D. But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.
Interventions
None listed
Sponsors
Pr. Semir Nouira
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Early CKD stage * Heart failure
Exclusion criteria
* Infections * cancer * corticoid therapy * renal replacement therapy * Advanced CKD stage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fibroblast Growth Factor 23 (FGF23) | completed data base (after 4 months) | compare the circulating levels of FGF23 (pg/ml) in the two groups . |
| Alpha Klotho | completed data base (after 4 months) | compare the circulating levels of klotho (ng/ml) in the two groups . |
Outcome results
None listed